Abstract: Objective: To investigate the protein expression of nuclear transcription factor NF-К B,VEGF-C and its receptor VEGFR-3 in breast cancers, and the correlations among NF-К B, VEGF-C,VEGFR-3 and histological grading and nodal status.Methods: Forty samples of human breast cancertissue and adjacent non-neoplastic breast tissue were examined for NF-К B, VEGF-C,VEGFR-3, aswell as HER2 and ER by immunohistochemistry.Results: The expressions of NF-К B in breast cancertissue and adjacent non-neoplastic breast tissue were 45.0%(18/40)and 30.0% (3/10, respectively. Theexpression of NF-К B in breast cancer has no significant difference compared to that in adjacent non-neoplastic breast tissue. NF-К B and HER2 expressions were positively correlated (r=0.442, P=0.004).The expression of NF-К B in the group of grade Ⅲ was increased compared to the other two groups (P=0.018). The positive rate of VEGF-C and VEGFR-3 in breast cancer were 70.0%(28/40)and 57.5%(23/40)respectively. The expression of VEGF-C and VEGFR-3 in breast cancer were increased in breastcancer (P<0.05), as compared with that in non-neoplastic breast tissue. The expression of VEGF-Ccorrelated significantly with VEGFR3 (r=0.761). Both NF-К B and HER2 were correlated with VEGF-C(r value were 0.373 and 0.342 respectively). The positive rate of VEGF-C and of VEGFR-3 were90.0% and 82.4% respectively in the lymph-node metastasis group, which was significantly higher than that of non-lymph node metastasis group (56.5% and 39.1% respectively). The number of VEGFR-3positive vessels in lymph-node metastasis group (8.44± 2.58) was significantly higher compared to thenon-lymph node metastasis group (5.12± 3.75).Conclusion: NF-К B is activated abnormally in part ofthe breast cancers. The expression of the NF-К B and of the HER2 protein positively correlate; bothNF-К B and HER2 expression positively correlate with VEGF-C. HER2, NF-К B, VEGF-C and VEG-FR-3 lies in a signaling pathway which promotes lymph node metastasis, hence NF-К B, VEGF-C andVEGFR-3 may be a hopeful therapeutic target for breast cancer.